Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright lifted their FY2026 earnings estimates for Entrada Therapeutics in a note issued to investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.99) per share for the year, up from their prior forecast of ($4.19). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is ($4.12) per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q4 2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.89) EPS and FY2027 earnings at ($3.29) EPS.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.07. Entrada Therapeutics had a negative net margin of 4,057.98% and a negative return on equity of 64.00%. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $2.30 million.
Several other brokerages have also weighed in on TRDA. UBS Group reissued a "neutral" rating on shares of Entrada Therapeutics in a report on Monday, October 19th. Weiss Ratings upgraded Entrada Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. Wall Street Zen upgraded Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, November 9th. Finally, Roth Capital reaffirmed a "buy" rating and set a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $17.75.
Read Our Latest Stock Report on TRDA
Entrada Therapeutics Stock Performance
NASDAQ:TRDA opened at $5.09 on Monday. Entrada Therapeutics has a 12 month low of $4.11 and a 12 month high of $16.45. The firm's 50 day moving average is $5.60 and its 200 day moving average is $8.42. The stock has a market capitalization of $199.27 million, a PE ratio of -1.33 and a beta of -0.19.
Hedge Funds Weigh In On Entrada Therapeutics
A number of large investors have recently made changes to their positions in the stock. 5AM Venture Management LLC purchased a new stake in shares of Entrada Therapeutics in the second quarter worth about $29,854,949. BlackRock Inc. bought a new position in shares of Entrada Therapeutics in the second quarter valued at approximately $19,013,000. Nantahala Capital Management LLC purchased a new position in Entrada Therapeutics during the second quarter valued at approximately $2,212,232. GSA Capital Partners LLP purchased a new position in Entrada Therapeutics during the second quarter valued at approximately $648,000. Finally, Bank of New York Mellon Corp purchased a new position in Entrada Therapeutics during the second quarter valued at approximately $582,000. 86.39% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.06, for a total value of $102,857.14. Following the completion of the transaction, the insider directly owned 4,318,348 shares in the company, valued at approximately $30,487,536.88. The trade was a 0.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $7.13, for a total transaction of $205,607.81. Following the completion of the transaction, the insider owned 3,885,115 shares of the company's stock, valued at $27,700,869.95. This represents a 0.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 495,947 shares of company stock worth $3,600,470 over the last 90 days. 9.49% of the stock is currently owned by corporate insiders.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company's research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.